Advertisement
Screener

AARDVARK THERAPEUTICS, INC. (AARD) Graph

AARD Revenue Flow

Filed revenue amounts for 2026-01-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue including tax (m); Research and development $10.46M; Operating expenses $15.08M; Net income -$14.39M.
  • 2026-03-31: Revenue including tax $0.00; Research and development $16.57M; Operating expenses $22.46M; Net income -$21.59M.
  • 2025-12-31: Revenue including tax $0.00*; Research and development $14.30M*; Operating expenses $18.70M*; Net income -$17.60M*.
  • 2025-09-30: Revenue including tax (m); Research and development $13.74M; Operating expenses $17.70M; Net income -$16.32M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AARD revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$37.55MOperating income-$37.55MResearch & development$27.02MNet income-$35.98M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenue including taxResearch and developmentOperating expensesNet income
2026-06-30(m)$10.46M$15.08M-$14.39M
2026-03-31$0.00$16.57M$22.46M-$21.59M
2025-12-31$0.00*$14.30M*$18.70M*-$17.60M*
2025-09-30(m)$13.74M$17.70M-$16.32M
2025-06-30(m)$13.14M$15.85M-$14.37M
2025-03-31$0.00$7.75M$10.47M-$9.31M
2024-09-30(m)$4.07M$5.09M-$4.18M
2024-06-30(m)$4.03M$6.07M-$5.45M
2024-03-31(m)$1.21M$2.17M-$2.18M

Revenue and expense 6 month

Period endRevenue including taxResearch and developmentOperating expensesNet income
2026-06-30$0.00$27.02M$37.55M-$35.98M
2025-06-30$0.00$20.90M$26.32M-$23.68M
2024-06-30(m)$5.24M$8.24M-$7.63M

Revenue and expense 9 month

Period endRevenue including taxResearch and developmentOperating expensesNet income
2025-09-30$0.00$34.64M$44.02M-$39.99M
2024-09-30(m)$9.30M$13.34M-$11.81M

Revenue and expense 12 month

Period endRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$48.94M$62.73M$0.00-$57.59M
2024-12-31(m)$17.36M$22.79M$0.00-$20.59M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
MEDICINOVA INC (MNOV)United States$0.130B-6.04
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31